Literature DB >> 2564738

Prenatal exclusion testing for Huntington disease using the polymerase chain reaction.

I McIntosh1, A Curtis, F A Millan, D J Brock.   

Abstract

Prenatal exclusion of Huntington disease (HD) may be carried out by analysis of cosegregating DNA markers on a first-trimester chorionic villus sample. The conventional Southern blot method is time-consuming and requires microgram quantities of DNA and milligram quantities of villus tissue. The use of the polymerase chain reaction (PCR) to amplify genomic DNA by a factor of 10(7) or more makes it possible to do analyses on very small samples in a few hours and without recourse to Southern blotting or hybridization with radioactive probes. We report on a fetus at risk of HD; prenatal testing was carried out by using the PCR to amplify a polymorphic DNA sequence adjacent to the HD locus. The risk of the fetus inheriting the HD gene could not be excluded and the pregnancy was terminated. This represents an example of gene tracking by using amplification of a restriction fragment length polymorphism at some distance from the relevant mutation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564738     DOI: 10.1002/ajmg.1320320232

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  4 in total

Review 1.  Molecular biology made easy. The polymerase chain reaction.

Authors:  A M Clarke; N P Mapstone; P Quirke
Journal:  Histochem J       Date:  1992-12

2.  Options for prenatal testing for Huntington's disease using linked DNA probes.

Authors:  D J Brock; A Curtis; M Mennie; J A Raeburn
Journal:  J Med Genet       Date:  1990-01       Impact factor: 6.318

3.  A consortium approach to molecular genetic services. Scottish Molecular Genetics Consortium.

Authors:  D J Brock
Journal:  J Med Genet       Date:  1990-01       Impact factor: 6.318

4.  Significant linkage disequilibrium between the Huntington's disease locus and markers at loci D4S10, D4S95, and D4S111 in Northern Ireland.

Authors:  P J Morrison; C A Graham; N C Nevin
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.